Vancomycin or Daptomycin Plus a β-Lactam Versus Vancomycin or Daptomycin Alone for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections: A Systematic Review and Meta-Analysis

2021 ◽  
Author(s):  
Yi-Hu Yi ◽  
Jiang-Lin Wang ◽  
Wen-Jun Yin ◽  
Wei-Hua Xu
Keyword(s):  
Systematic Review ◽  
Staphylococcus Aureus ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Meta Analysis ◽  
Bloodstream Infections ◽  
Methicillin Resistant

scholarly journals Prevalence, predictors, and mortality of bloodstream infections due to methicillin-resistant Staphylococcus aureus in patients with malignancy: systemic review and meta-analysis

2020 ◽  
Author(s):  
Zhouqi Li ◽  
Hemu Zhuang ◽  
Guannan Wang ◽  
Hui Wang ◽  
Ying Dong
Keyword(s):  
Staphylococcus Aureus ◽  
Cancer Patients ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Eastern Mediterranean ◽  
Meta Analysis ◽  
Bloodstream Infections ◽  
Systemic Review ◽  
Primary Data ◽  
Methicillin Resistant ◽  
Pooled Prevalence

Abstract Background: Cancer patients are more likely to develop and die of bloodstream infection (BSI) than noncancer patients. Methicillin-resistant Staphylococcus aureus (MRSA), which is associated with immense mortality and economic burden worldwide, is not covered by the recommended initial antibiotic therapy for cancer patients with BSI. This systemic review was performed to estimate the global methicillin-resistant Staphylococcus aureus (MRSA) prevalence among bacteremia in patients with malignancy, and further study the predictors and mortality of cancer patients with MRSA bacteremia.Methods: The PubMed and EMBASE databases were searched for studies published from Jan. 2000 to Mar. 2020 that provided primary data on the prevalence, predictors, or mortality of MRSA bacteremia in cancer patients. A random-effects model meta-analysis was performed to estimate the pooled prevalence of MRSA with 95% confidence intervals (95% CIs).Results: The pooled prevalence of MRSA was 3% (95% CI 2–5%) among all bloodstream infections (BSIs) and 44% (95% CI 32–57%) among S. aureus bacteremia in cancer patients. Based on geographical stratification, the pooled prevalence was 5% in Africa (95% CI 1–14%), 1% in Americas (95% CI 1–2%), 2% in Europe (95% CI 1–4%), 4% in Western Pacific (95% CI 2–7%), 8% in South-east Asia (95% CI 4–14%) and 0% in Eastern Mediterranean (95% CI 0–3%). No significant temporal change in MRSA rates was detected in this analysis (R2 = 0.06; P=0.24). Predictors for MRSA BSIs among cancer patients were identified by comparison with their methicillin-susceptible counterparts, and they were mainly related to healthcare-associated infections and immunosuppression. Finally, the 60-day mortality in adult cancer patients with MRSA BSIs was reported to be 12%, and the 6-month overall mortality was 43.2%, with community-onset infection, secondary BSI, and vancomycin MIC≥2g/mL being the risk factors for mortality.Conclusions: Although the prevalence of MRSA BSIs among cancer patients is relatively low, it did not decline over time as MRSA BSIs in the general hospital population and the high mortality rate was related to MRSA BSIs in patients with malignancy.

Prevalence of methicillin-resistant Staphylococcus aureus isolated from burn patients in Iran: A systematic review and meta-analysis

2018 ◽  
Vol 12 ◽  
pp. 202-206 ◽  
Author(s):  
Mohammad Emaneini ◽  
Reza Beigverdi ◽  
Willem B. van Leeuwen ◽  
Hosseinali Rahdar ◽  
Morteza Karami-Zarandi ◽  
...  
Keyword(s):  
Systematic Review ◽  
Staphylococcus Aureus ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Meta Analysis ◽  
Burn Patients ◽  
Methicillin Resistant
Sign in / Sign up

Export Citation Format

Share Document